Scientific Publications

Science

Publications and Posters

Belumosudil (KD025) and cGVHD


  • Belumosudil for Chronic Graft-versus-Host Disease (cGVHD) After 2 or More Prior Lines of Therapy: The ROCKstar Study. Blood. .
    Read More

  • Follow-up Analysis of KD025-213 (the ROCKstar Study): A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Patients With cGVHD. European Hematology Association. .
    View

  • ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology. .
    View

  • Presentation and Management of cGVHD in Real-World Clinical Practice: A Medical Chart Audit. European Hematology Association. .
    View

  • Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation (HCT): A U.S. Claims Analysis. ASH Annual Meeting and Exposition. .
    View

Immuno-oncology: IL-15 Fusion Protein Platform


  • Targeted IL-15 Immunotherapy Platform. .
    View

  • A Phase I Dose Escalation of KD033, a PDL1-IL15 Bispecific Molecule, in Advanced Solid Tumors. American Society of Clinical Oncology. .
    View

  • A Phase 1 Multiple Ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors.. American Association for Cancer Research. .
    View

  • Single-Dose Anti PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses. Molecular Cancer Therapeutics. .
    View

  • A novel human anti-PD1/IL15 bi-functional protein with robust anti-tumor activity and low systemic toxicity. The Society for Immunotherapy of Cancer. .
    View

  • Anti-PD-L1/IL15 fusion protein KD033 demonstrated efficient T cell redirected killing of PD-L1 expressing target cells and in vivo efficacy that correlated to its retention in tumors. American Association for Cancer Research. .
    View

  • A novel anti-PD1-IL-15 immunocytokine potentiates anti-tumor T cell activity of PD-1 checkpoint blockade and IL-2/15R-beta-gamma agonism. American Association for Cancer Research. .
    View

  • Anti-PDL1/IL-15 fusion protein increases efficacy-associated rare effector cells in cynomolgus monkey and mouse peripheral blood. European Society for Medical Oncology. .
    View

  • Synergistic efficacy of anti-PD-L1/IL-15 fusion protein in combination with anti-CTLA-4 antibody in a murine orthotopic 4T1 breast carcinoma model. Society for Immunotherapy of Cancer. .
    View

ROCK Inhibition – Preclinical


  • Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. .
    Read More

  • Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. PNAS. .
    Read More

  • Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. The Journal of Immunology. .
    Read More

  • ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings. Sci. Signal. .
    Read More

  • Isoform-specific targeting of ROCK proteins in immune cells. Small GTPases. .
    Read More

  • ROCKing cytokine secretion balance in human T cells. Cytokine. .
    Read More

  • Selective ROCK2 inhibition in focal cerebral ischemia. ANA. .
    Read More